Theresa H M Keegan1,2, Raymon H Grogan3, Helen M Parsons4, Li Tao1, Michael G White3, Kenan Onel5, Pamela L Horn-Ross1,2. 1. 1Cancer Prevention Institute of California, Fremont, California. 2. 2Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California. 3. 3Endocrine Surgery Research Program, Department of Surgery, University of Chicago, Pritzker School of Medicine, Chicago Illinois. 4. 4Department of Epidemiology and Biostatistics, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. 5. 5Department of Pediatrics, University of Chicago, Chicago, Illinois.
Abstract
BACKGROUND: Few studies have focused on prognostic factors among adolescents and young adults (AYAs) 15 to 39 years of age when diagnosed with differentiated thyroid cancer (DTC). Our study expands upon prior work by including an evaluation of survival among AYA men and by neighborhood socioeconomic status, health insurance, and clinical factors to identify subgroups of young DTC patients at higher risk of mortality. METHODS: Data for 16,827 AYA DTC patients diagnosed between 1988 and 2010 were obtained from the California Cancer Registry. Survival, through 2010, by sociodemographic and clinical factors was analyzed using Cox proportional hazards regression. RESULTS: Of the 2.1% of AYAs who died, 16.7% died from thyroid cancer and 21.4% died from a subsequent cancer. In multivariate analyses, older AYAs 35 to 39 year of age (versus 15- to 29-year-olds), men (hazard ratio [HR] 2.77, 95% confidence interval [CI] 1.62-4.72), and AYAs of African American or Hispanic race/ethnicity (versus non-Hispanic whites) had worse thyroid cancer specific survival. In addition, residing in low socioeconomic status neighborhoods (HR 3.11 [CI 1.28-7.56]) and nonmetropolitan areas (HR 5.53 [CI 2.07-14.78]) was associated with worse thyroid cancer-specific survival among AYA men, but not AYA women. CONCLUSIONS: Despite the generally good prognosis among AYAs with DTC, we identified subgroups of AYA patients at risk for poor outcomes. Further study of the factors underlying these associations, including possible barriers to receiving high-quality treatment and follow-up care, as well as lifestyle factors, are critical to reducing these disparities.
BACKGROUND: Few studies have focused on prognostic factors among adolescents and young adults (AYAs) 15 to 39 years of age when diagnosed with differentiated thyroid cancer (DTC). Our study expands upon prior work by including an evaluation of survival among AYA men and by neighborhood socioeconomic status, health insurance, and clinical factors to identify subgroups of young DTC patients at higher risk of mortality. METHODS: Data for 16,827 AYA DTC patients diagnosed between 1988 and 2010 were obtained from the California Cancer Registry. Survival, through 2010, by sociodemographic and clinical factors was analyzed using Cox proportional hazards regression. RESULTS: Of the 2.1% of AYAs who died, 16.7% died from thyroid cancer and 21.4% died from a subsequent cancer. In multivariate analyses, older AYAs 35 to 39 year of age (versus 15- to 29-year-olds), men (hazard ratio [HR] 2.77, 95% confidence interval [CI] 1.62-4.72), and AYAs of African American or Hispanic race/ethnicity (versus non-Hispanic whites) had worse thyroid cancer specific survival. In addition, residing in low socioeconomic status neighborhoods (HR 3.11 [CI 1.28-7.56]) and nonmetropolitan areas (HR 5.53 [CI 2.07-14.78]) was associated with worse thyroid cancer-specific survival among AYA men, but not AYA women. CONCLUSIONS: Despite the generally good prognosis among AYAs with DTC, we identified subgroups of AYA patients at risk for poor outcomes. Further study of the factors underlying these associations, including possible barriers to receiving high-quality treatment and follow-up care, as well as lifestyle factors, are critical to reducing these disparities.
Authors: Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton Journal: J Clin Endocrinol Metab Date: 2012-06-22 Impact factor: 5.958
Authors: Sharon H Giordano; Yong-Fang Kuo; Zhigang Duan; Gabriel N Hortobagyi; Jean Freeman; James S Goodwin Journal: Cancer Date: 2008-06 Impact factor: 6.860
Authors: Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Brian C-H Chiu; Peter Angelos; Raymon H Grogan Journal: Ann Surg Oncol Date: 2013-03-17 Impact factor: 5.344
Authors: Kevin Y Urayama; Julie Von Behren; Peggy Reynolds; Andrew Hertz; Monique Does; Patricia A Buffler Journal: Ann Epidemiol Date: 2009-04-11 Impact factor: 3.797
Authors: Ayal A Aizer; Benjamin Falit; Mallika L Mendu; Ming-Hui Chen; Toni K Choueiri; Karen E Hoffman; Jim C Hu; Neil E Martin; Quoc-Dien Trinh; Brian M Alexander; Paul L Nguyen Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Michael G White; Nicole A Cipriani; Layth Abdulrasool; Sharone Kaplan; Briseis Aschebrook-Kilfoy; Peter Angelos; Edwin L Kaplan; Raymon H Grogan; Kenan Onel Journal: Thyroid Date: 2016-08 Impact factor: 6.568
Authors: Theresa H M Keegan; Lawrence H Kushi; Qian Li; Ann Brunson; X Chawla; Helen K Chew; Marcio Malogolowkin; Ted Wun Journal: J Cancer Surviv Date: 2018-02-09 Impact factor: 4.442
Authors: Chelsea Anderson; Jennifer L Lund; Mark A Weaver; William A Wood; Andrew F Olshan; Hazel B Nichols Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-17 Impact factor: 4.254
Authors: Amy M Berkman; Abenaa M Brewster; Lee W Jones; Jun Yu; J Jack Lee; S Andrew Peng; Abigail Crocker; Joann L Ater; Susan C Gilchrist Journal: J Adolesc Young Adult Oncol Date: 2017-05-22 Impact factor: 2.223
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J Andrew Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-08 Impact factor: 4.254